Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results